Send In The Senolytics

Elie Dolgin's recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development - including work by SRF's Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.
Campisi_Senolysis_Figure
Credit: Judith Campisi, Buck Institute

Elie Dolgin’s recent article in Nature Biotechnology explains why the apparent failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

Share on facebook
Share on twitter
Share on reddit
Share on linkedin
Share on google
Share on email

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2021 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can